Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 Oct;29(10):2104-7.
doi: 10.1038/leu.2015.76. Epub 2015 Mar 16.

Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia

R B Walter  1   2   3 , M Othus  4 , E M Paietta  5 , J Racevskis  5 , H F Fernandez  6 , J-W Lee  7 , Z Sun  7 , M S Tallman  8 , J Patel  9 , M Gönen  10 , O Abdel-Wahab  8   9 , R L Levine  8   9 , E H Estey  1   2
Affiliations
Clinical Trial

Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia

R B Walter et al. Leukemia. 2015 Oct.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Prediction of Resistance and Survival.
Importance of individual covariates to predict (A) failure to attain CR despite surviving at least 28 days from beginning induction therapy (“primary refractoriness”), (B) primary refractoriness or relapse-free survival (RFS) ≤3 months, (C) primary refractoriness or RFS ≤6 months, (D) primary refractoriness or RFS ≤12 months, and (E) overall survival using Chi-squared (χ2) values. “Importance” is evaluated with the Wald χ2 statistic minus the predictor’s degrees of freedom (df). Covariates with larger χ2 values are considered more “important” in predicting the outcome of interest. Covariates are listed on the y-axis in order of their χ2 values, with lowest values at the top and highest values at the bottom.
See this image and copyright information in PMC

References

    1. Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet. 2013;9865;381:484–495. - PubMed
    1. Walter RB, Othus M, Burnett AK, Lowenberg B, Kantarjian HM, Ossenkoppele GJ, et al. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia. 2015;2;29:312–320. - PMC - PubMed
    1. Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;12;366:1079–1089. - PMC - PubMed
    1. Gönen M, Sun Z, Figueroa ME, Patel JP, Abdel-Wahab O, Racevskis J, et al. CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood. 2012;11;120:2297–2306. - PMC - PubMed
    1. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;13;361:1249–1259. - PMC - PubMed

Publication types

MeSH terms

Associated data